San Francisco, June 28th,2018 – Recardio Inc. today announced that it has expanded its Management Board, reflecting the companies expansion of clinical development in 2018.
Recardio initiates patient recruitment for Phase 2 Study Study of Dutogliptin in Combination With Filgrastim in Post-Myocardial Infarction
San Francisco, May 28, 2018 – Recardio Inc., a life science company developing regenerative therapies for cardiovascular diseases, announced that it is starting recruiting patients for its Phase 2 study of dutogliptin in combination with filgrastim in early recovery post-myocardial infarction. Recruitment for this randomized, double-blind, placebo-controlled trial will begin in one of the 29 participating trial centers in the European Union and be expanded rapidly to also include 5 centers in the United States.
Recardio receives FDA approval for Phase 2 Study
San Francisco, January 31st, 2018 – Recardio Inc. today announced that it has received the FDA approval for its Phase 2 study of dutogliptin in combination with filgrastim in early recovery post-myocardial infarction.
Recardio presented at BIO Investor Forum 2017 in San Francisco
San Francisco, Oct. 17, 2017 – Recardio presented today its clinical regenerative therapy program for cardiovascular diseases at the international BIO Investor Forum 2017 in San Francisco.
Recardio completes Phase 1 Study
San Francisco, October 12th, 2017 – Recardio Inc. successfully completes Phase 1 study for Dutogliptin.